Breath Therapeutics CEO on aerosol therapy pipeline

Dr. Jens Stegemann, CEO of Breath Therapeutics, talks to Scrip's Lucie Ellis about progress at the company since the closing of its March 2017 series A financing round, and the company's development portfolio of aerosol drugs. Breath raised USD 46 million via a series A financing in March this year to develop advanced drug-aerosol therapeutics in pulmonary orphan indications. Its lead program, a first-in-class inhalation therapy for treatment of Bronchiolitis Obliterans Syndrome in patients after lung transplantation, is ready to enter Phase III. Stegemann expects enrollment to begin for this late-stage study in 2018.